Top Movers

Company Announcements

Total Voting Rights

Related Companies

RNS Number : 5538W
Vernalis PLC
29 April 2016
 

TOTAL VOTING RIGHTS

 

VERNALIS PLC (the "Company")

 

29 April 2016

 

Vernalis plc (LSE: VER) announces that for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 445,133,540 ordinary shares of 1p each, with one voting right per share. There are no shares held in treasury.

 

The total number of voting rights in the Company is therefore 445,133,540.

 

The above figure of 445,133,540 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

-  Ends  -

 

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer


David Mackney, Chief Financial Officer

 


Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8000

Dr Julian Feneley


Henry Fitzgerald-O'Connor


Rupert Winckler


Emma Gabriel

 


Shore Capital (Joint Broker):

+44 (0) 20 7408 4090

Bidhi Bhoma


Toby Gibbs

 


FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell

Simon Conway

Stephanie Cuthbert


 

Notes to Editors

 

About Vernalis

Vernalis is a revenue-generating, specialty pharmaceutical company with significant expertise in drug development. The Company has three approved products: Tuzistra® XR targeting the US prescription cough cold market; Moxatag®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and paediatric patients 12 years and older; and frovatriptan (Frova®) for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis also has significant expertise in fragment- and structure-based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo Pharmaceuticals Inc., GlaxoSmithKline, Genentech, H. Lundbeck A/S, Menarini, Novartis Institutes for BioMedical Research, Servier, Taisho Pharmaceutical Co. Ltd., and Tris.

 

For further information about Vernalis, please visit www.vernalis.com.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRUBRSRNVASUAR

Top of Page